umu.sePublikationer
Ändra sökning
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf
Targeting glucosylceramide synthase induction of cell surface globotriaosylceramide (Gb3) in acquired cisplatin-resistance of lung cancer and malignant pleural mesothelioma cells
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Klinisk kemi. (Kjell Grankvist)ORCID-id: 0000-0002-4968-6192
Umeå universitet, Medicinska fakulteten, Institutionen för odontologi, Tandläkarutbildning. (Aa-gruppen)
Umeå universitet, Medicinska fakulteten, Institutionen för strålningsvetenskaper, Onkologi.
Umeå universitet, Medicinska fakulteten, Institutionen för medicinsk biovetenskap, Klinisk kemi.
Visa övriga samt affilieringar
2015 (Engelska)Ingår i: Experimental Cell Research, ISSN 0014-4827, E-ISSN 1090-2422, Vol. 336, nr 1, s. 23-32Artikel i tidskrift (Refereegranskat) Published
Abstract [en]

BACKGROUND: Acquired resistance to cisplatin treatment is a caveat when treating patients with non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM). Ceramide increases in response to chemotherapy, leading to proliferation arrest and apoptosis. However, a tumour stress activation of glucosylceramide synthase (GCS) follows to eliminate ceramide by formation of glycosphingolipids (GSLs) such as globotriaosylceramide (Gb3), the functional receptor of verotoxin-1. Ceramide elimination enhances cell proliferation and apoptosis blockade, thus stimulating tumor progression. GSLs transactivate multidrug resistance 1/P-glycoprotein (MDR1) and multidrug resistance-associated protein 1 (MRP1) expression which further prevents ceramide accumulation and stimulates drug efflux. We investigated the expression of Gb3, MDR1 and MRP1 in NSCLC and MPM cells with acquired cisplatin resistance, and if GCS activity or MDR1 pump inhibitors would reduce their expression and reverse cisplatin-resistance.

METHODS: Cell surface expression of Gb3, MDR1 and MRP1 and intracellular expression of MDR1 and MRP1 was analysed by flow cytometry and confocal microscopy on P31 MPM and H1299 NSCLC cells and subline cells with acquired cisplatin resistance. The effect of GCS inhibitor PPMP and MDR1 pump inhibitor cyclosporin A for 72h on expression and cisplatin cytotoxicity was tested.

RESULTS: The cisplatin-resistant cells expressed increased cell surface Gb3. Cell surface Gb3 expression of resistant cells was annihilated by PPMP whereas cyclosporin A decreased Gb3 and MDR1 expression in H1299 cells. No decrease of MDR1 by PPMP was noted in using flow cytometry, whereas a decrease of MDR1 in H1299 and H1299res was indicated with confocal microscopy. No certain co-localization of Gb3 and MDR1 was noted. PPMP, but not cyclosporin A, potentiated cisplatin cytotoxicity in all cells.

CONCLUSIONS: Cell surface Gb3 expression is a likely tumour biomarker for acquired cisplatin resistance of NSCLC and MPM cells. Tumour cell resistance to MDR1 inhibitors of cell surface MDR1 and Gb3 could explain the aggressiveness of NSCLC and MPM. Therapy with GCS activity inhibitors or toxin targeting of the Gb3 receptor may substantially reduce acquired cisplatin drug resistance of NSCLC and MPM cells.

Ort, förlag, år, upplaga, sidor
2015. Vol. 336, nr 1, s. 23-32
Nyckelord [en]
Cisplatin,  Glucosylceramide synthase (GCS),  Globotriaosylceramide (Gb3),  Lung cancer,  Multidrug resistance 1/P-glycoprotein (MDR1), Multidrug resistance-associated protein 1 (MRP1),  Malignant pleural mesothelioma (MPM),  DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP),  Cyclosporin A,  Acquired drug resistance
Nationell ämneskategori
Medicinsk bioteknologi
Identifikatorer
URN: urn:nbn:se:umu:diva-103786DOI: 10.1016/j.yexcr.2015.05.012ISI: 000358821700003PubMedID: 26004871OAI: oai:DiVA.org:umu-103786DiVA, id: diva2:815389
Forskningsfinansiär
CancerfondenTillgänglig från: 2015-05-30 Skapad: 2015-05-30 Senast uppdaterad: 2018-06-07Bibliografiskt granskad
Ingår i avhandling
1. Targeting Gb3 and apoptosis-related proteins to overcome cisplatin resistance
Öppna denna publikation i ny flik eller fönster >>Targeting Gb3 and apoptosis-related proteins to overcome cisplatin resistance
2016 (Engelska)Doktorsavhandling, sammanläggning (Övrigt vetenskapligt)
Alternativ titel[sv]
Gb3 och apoptos-relaterade proteiner som måltavla för att bryta cisplatinresistens
Abstract [en]

Background Cisplatin is used for treatment of malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC) but treatment with cisplatin often leads to acquired resistance to cisplatin, resulting in poor patient survival. Globotriaosylceramide (Gb3) and multidrug resistance protein 1 (MDR1) have been associated with cisplatin resistance. Gb3 serves as a receptor for verotoxin-1 (VT-1), which induces apoptosis, and has been shown to have a functional dependency to MDR1 and heat shock protein 70 (HSP7o). The Bcl-2 family of proteins and inhibitors of apoptosis (IAPs) are key regulators of apoptosis. BH3-mimetics mimic pro-apoptotic BH3-only proteins, while Smac mimetics mimic the IAP-binding protein Smac/Diablo. These drugs have shown great promise in reversing cisplatin resistance. Exosomes are small bio-nanoparticles secreted and taken up by both cancer cells and normal cells. They have the ability to transfer properties between cells and have been shown to confer resistance to cisplatin.

Methods In this thesis, NSCLC cell line H1299 and MPM cell line P31 were studied using western blot, flow cytometry, proteome profilers, confocal microscopy and gene expression arrays to investigate changes in protein and gene expression after acquisition of cisplatin resistance (P31res and H1299res) or after incubation with exosomes or drugs that target these. The cytotoxic and apoptotic effects were studied using fluorometric cytotoxicity assay (FMCA) and terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay.

Results This thesis confirms that Gb3 is a potential target for cisplatin resistance reversal. Incubation with glycosphingolipid production inhibitor DL-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol (PPMP) and VT-1 led to reduced Gb3 cell surface expression and increased cytotoxic effect of cisplatin in all cell lines. Gb3 and MDR1 was not co-localized in any studied cell line, but Gb3 and HSP70 were co-localized on the cell surface and PPMP and VT-1 led to a decrease of both Gb3 and HSP70. Both BH3-mimetic obatoclax and Smac mimetic AT-406 had an additive effect on cisplatin-induced cytotoxicity and apoptosis in P31 and a synergistic effect in P31res. Results indicate that exosomes from cisplatin-resistant cell lines can transfer HSP70 to the surface of cells.

Conclusion Cell surface Gb3 and HSP70, the Bcl-2/IAP-family proteins and exosomal transfer of cisplatin resistance characteristics are potential targets in combatting cisplatin resistance that show therapeutic promise and warrant further research.

Ort, förlag, år, upplaga, sidor
Umeå: Umeå Universitet, 2016. s. 48
Serie
Umeå University medical dissertations, ISSN 0346-6612 ; 1807
Nyckelord
Cisplatin resistance, exosomes, gb3, HSP70, the Bcl-2 family
Nationell ämneskategori
Cell- och molekylärbiologi
Forskningsämne
cellforskning; medicinsk cellbiologi; onkologi
Identifikatorer
urn:nbn:se:umu:diva-119778 (URN)978-91-7601-475-2 (ISBN)
Disputation
2016-05-23, E04, By 6E, Nod R, Norrlands universitetssjukhus, 901 85 Umeå, Umeå, 13:00 (Engelska)
Opponent
Handledare
Forskningsfinansiär
Cancerfonden, CAN 2011/599
Tillgänglig från: 2016-05-02 Skapad: 2016-04-26 Senast uppdaterad: 2018-06-07Bibliografiskt granskad

Open Access i DiVA

fulltext(1019 kB)106 nedladdningar
Filinformation
Filnamn FULLTEXT01.pdfFilstorlek 1019 kBChecksumma SHA-512
6ddd6536adfca960c7c63897cf93d2e1c408cae7724747fa17dbd9fb982b8228d78bfa84464e5826631629b61e505d10141d716f4d54bce5e5a75c23d77752d5
Typ fulltextMimetyp application/pdf

Övriga länkar

Förlagets fulltextPubMed

Personposter BETA

Tyler, AndreasJohansson, AndersKarlsson, TereseKumar Gudey, ShyamBrännström, ThomasGrankvist, KjellBehnam-Motlagh, Parviz

Sök vidare i DiVA

Av författaren/redaktören
Tyler, AndreasJohansson, AndersKarlsson, TereseKumar Gudey, ShyamBrännström, ThomasGrankvist, KjellBehnam-Motlagh, Parviz
Av organisationen
Klinisk kemiTandläkarutbildningOnkologiPatologi
I samma tidskrift
Experimental Cell Research
Medicinsk bioteknologi

Sök vidare utanför DiVA

GoogleGoogle Scholar
Totalt: 106 nedladdningar
Antalet nedladdningar är summan av nedladdningar för alla fulltexter. Det kan inkludera t.ex tidigare versioner som nu inte längre är tillgängliga.

doi
pubmed
urn-nbn

Altmetricpoäng

doi
pubmed
urn-nbn
Totalt: 354 träffar
RefereraExporteraLänk till posten
Permanent länk

Direktlänk
Referera
Referensformat
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Annat format
Fler format
Språk
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Annat språk
Fler språk
Utmatningsformat
  • html
  • text
  • asciidoc
  • rtf